Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Enrico Mini

Showing results (111-120 of 134) with videos related to

Pageof 14
Sort By:
Plos One|December 4, 2015
HLA-G 3'UTR Polymorphisms Impact the Prognosis of Stage II-III CRC Patients in Fluoropyrimidine-Based TreatmentMarica Garziera, Ettore Bidoli, Erika Cecchin, et al.
Leukemia & Lymphoma|December 3, 2013
Identification of pharmacogenomic markers of clinical efficacy in a dose-dense therapy regimen (R-CHOP14) in diffuse large B-cell lymphomaStefania Nobili, Cristina Napoli, Benedetta Puccini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 21, 2018
Prognostic Value of Methylator Phenotype in Stage III Colon Cancer Treated with Oxaliplatin-based Adjuvant ChemotherapyClaire Gallois, Julien Taieb, Delphine Le Corre, et al.
Frontiers in Pharmacology|October 20, 2018
A Clinical-Genetic Score to Identify Surgically Resected Colorectal Cancer Patients Benefiting From an Adjuvant Fluoropyrimidine-Based TherapyElena De Mattia, Eva Dreussi, Marcella Montico, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|July 3, 2019
Carcinoembryonic Antigen Levels and Survival in Stage III Colon Cancer: <i>Post hoc</i> Analysis of the MOSAIC and PETACC-8 TrialsEdouard Auclin, Julien Taieb, Come Lepage, et al.
European Journal of Cancer (Oxford, England : 1990)|December 20, 2020
Prognostic variables in low and high risk stage III colon cancers treated in two adjuvant chemotherapy trialsFrank A Sinicrope, Sakti Chakrabarti, Pierre Laurent-Puig, et al.
European Journal of Cancer (Oxford, England : 1990)|June 27, 2017
Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOXJean-François Emile, Catherine Julié, Karine Le Malicot, et al.
Journal of the National Cancer Institute|January 2, 2017
Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon CancerJulien Taieb, Karine Le Malicot, Qian Shi, et al.
Oncology Research|March 1, 2008
Analysis of gene expression profiles reveals novel correlations with the clinical course of colorectal cancerDuccio Cavalieri, Piero Dolara, Enrico Mini, et al.
The Lancet. Oncology|June 15, 2014
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trialJulien Taieb, Josep Tabernero, Enrico Mini, et al.
Pageof 14

Showing results (111-120 of 134) with videos related to

Sort By:
Pageof 14
Plos One|December 4, 2015
HLA-G 3'UTR Polymorphisms Impact the Prognosis of Stage II-III CRC Patients in Fluoropyrimidine-Based TreatmentMarica Garziera, Ettore Bidoli, Erika Cecchin, et al.
Leukemia & Lymphoma|December 3, 2013
Identification of pharmacogenomic markers of clinical efficacy in a dose-dense therapy regimen (R-CHOP14) in diffuse large B-cell lymphomaStefania Nobili, Cristina Napoli, Benedetta Puccini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 21, 2018
Prognostic Value of Methylator Phenotype in Stage III Colon Cancer Treated with Oxaliplatin-based Adjuvant ChemotherapyClaire Gallois, Julien Taieb, Delphine Le Corre, et al.
Frontiers in Pharmacology|October 20, 2018
A Clinical-Genetic Score to Identify Surgically Resected Colorectal Cancer Patients Benefiting From an Adjuvant Fluoropyrimidine-Based TherapyElena De Mattia, Eva Dreussi, Marcella Montico, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|July 3, 2019
Carcinoembryonic Antigen Levels and Survival in Stage III Colon Cancer: <i>Post hoc</i> Analysis of the MOSAIC and PETACC-8 TrialsEdouard Auclin, Julien Taieb, Come Lepage, et al.
European Journal of Cancer (Oxford, England : 1990)|December 20, 2020
Prognostic variables in low and high risk stage III colon cancers treated in two adjuvant chemotherapy trialsFrank A Sinicrope, Sakti Chakrabarti, Pierre Laurent-Puig, et al.
European Journal of Cancer (Oxford, England : 1990)|June 27, 2017
Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOXJean-François Emile, Catherine Julié, Karine Le Malicot, et al.
Journal of the National Cancer Institute|January 2, 2017
Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon CancerJulien Taieb, Karine Le Malicot, Qian Shi, et al.
Oncology Research|March 1, 2008
Analysis of gene expression profiles reveals novel correlations with the clinical course of colorectal cancerDuccio Cavalieri, Piero Dolara, Enrico Mini, et al.
The Lancet. Oncology|June 15, 2014
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trialJulien Taieb, Josep Tabernero, Enrico Mini, et al.
Pageof 14